Treprostinil
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Aug 1, 2010 → Oct 5, 2016
NCT ID
NCT01268553About Treprostinil
Treprostinil is a approved stage product being developed by United Therapeutics for Pulmonary Arterial Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT01268553. Target conditions include Pulmonary Arterial Hypertension.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05564637 | Phase 2 | Completed |
| NCT04005469 | Phase 1/2 | Recruiting |
| NCT01028651 | Pre-clinical | Completed |
| NCT01268553 | Approved | Completed |
| NCT00705133 | Phase 2 | Completed |
| NCT00439946 | Approved | Terminated |
Competing Products
20 competing products in Pulmonary Arterial Hypertension